CalciMedica to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

LA JOLLA, Calif., Feb. 3, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that Rachel Leheny, Ph.D., Chief Executive Officer, will present at the Oppenheimer 35^th Annual Healthcare Life Sciences Conference on Wednesday, February 12, 2025, at 8:00 a.m. ET.

Read more at prnewswire.com